Cargando…

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report

INTRODUCTION: Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement pathway, resulting in microvascular thrombosis, organ ischemia and damage....

Descripción completa

Detalles Bibliográficos
Autores principales: Kourouklaris, Andreas, Ioannou, Kyriakos, Athanasiou, Ioannis, Panagidou, Alexia, Demetriou, Kiproulla, Zavros, Michalis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170201/
https://www.ncbi.nlm.nih.gov/pubmed/25219386
http://dx.doi.org/10.1186/1752-1947-8-307
_version_ 1782335804224307200
author Kourouklaris, Andreas
Ioannou, Kyriakos
Athanasiou, Ioannis
Panagidou, Alexia
Demetriou, Kiproulla
Zavros, Michalis
author_facet Kourouklaris, Andreas
Ioannou, Kyriakos
Athanasiou, Ioannis
Panagidou, Alexia
Demetriou, Kiproulla
Zavros, Michalis
author_sort Kourouklaris, Andreas
collection PubMed
description INTRODUCTION: Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement pathway, resulting in microvascular thrombosis, organ ischemia and damage. Prognosis is poor: up to 65 percent of patients require dialysis or have kidney damage of varying severity or die despite plasma exchange/plasma infusion treatment. CASE PRESENTATION: We describe the case of a 23-year-old woman of Hellenic origin who, after a preeclampsia-induced premature delivery, developed thrombotic microangiopathy with renal failure, tonicoclonic seizures, anasarca edema and hypertension. Intensive plasma exchange was initiated twice daily, in parallel to dialysis for one month. Three months later, our patient was discharged with nondialysis-dependent renal failure and without signs of hemolysis. Three months after discharge our patient was readmitted with cardiomyopathy (left ventricular ejection fraction of 25 percent) and signs and symptoms of thrombotic microangiopathy. Our patient was diagnosed with atypical hemolytic uremic syndrome and was started on eculizumab (a complement inhibitor), which improved clinical and laboratory parameters. However, a transient pause in treatment resulted in thrombotic microangiopathy relapse, which was rapidly blocked with reintroduction of eculizumab treatment. During long-term eculizumab treatment, thrombotic microangiopathy manifestations were inhibited and renal and cardiac function restored, with no need for other invasive treatments. CONCLUSIONS: Establishing the diagnosis of atypical hemolytic uremic syndrome in patients presenting with thrombotic microangiopathy is challenging since common symptoms are shared with other conditions like Shiga toxin-producing Escherichia coli hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. The described case illustrates the complexity and importance of rapid diagnosis in a rare disease and the need for appropriate and specific treatment for best long-term outcomes.
format Online
Article
Text
id pubmed-4170201
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41702012014-09-23 Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report Kourouklaris, Andreas Ioannou, Kyriakos Athanasiou, Ioannis Panagidou, Alexia Demetriou, Kiproulla Zavros, Michalis J Med Case Rep Case Report INTRODUCTION: Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement pathway, resulting in microvascular thrombosis, organ ischemia and damage. Prognosis is poor: up to 65 percent of patients require dialysis or have kidney damage of varying severity or die despite plasma exchange/plasma infusion treatment. CASE PRESENTATION: We describe the case of a 23-year-old woman of Hellenic origin who, after a preeclampsia-induced premature delivery, developed thrombotic microangiopathy with renal failure, tonicoclonic seizures, anasarca edema and hypertension. Intensive plasma exchange was initiated twice daily, in parallel to dialysis for one month. Three months later, our patient was discharged with nondialysis-dependent renal failure and without signs of hemolysis. Three months after discharge our patient was readmitted with cardiomyopathy (left ventricular ejection fraction of 25 percent) and signs and symptoms of thrombotic microangiopathy. Our patient was diagnosed with atypical hemolytic uremic syndrome and was started on eculizumab (a complement inhibitor), which improved clinical and laboratory parameters. However, a transient pause in treatment resulted in thrombotic microangiopathy relapse, which was rapidly blocked with reintroduction of eculizumab treatment. During long-term eculizumab treatment, thrombotic microangiopathy manifestations were inhibited and renal and cardiac function restored, with no need for other invasive treatments. CONCLUSIONS: Establishing the diagnosis of atypical hemolytic uremic syndrome in patients presenting with thrombotic microangiopathy is challenging since common symptoms are shared with other conditions like Shiga toxin-producing Escherichia coli hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. The described case illustrates the complexity and importance of rapid diagnosis in a rare disease and the need for appropriate and specific treatment for best long-term outcomes. BioMed Central 2014-09-14 /pmc/articles/PMC4170201/ /pubmed/25219386 http://dx.doi.org/10.1186/1752-1947-8-307 Text en Copyright © 2014 Kourouklaris et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Kourouklaris, Andreas
Ioannou, Kyriakos
Athanasiou, Ioannis
Panagidou, Alexia
Demetriou, Kiproulla
Zavros, Michalis
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title_full Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title_fullStr Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title_full_unstemmed Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title_short Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
title_sort postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170201/
https://www.ncbi.nlm.nih.gov/pubmed/25219386
http://dx.doi.org/10.1186/1752-1947-8-307
work_keys_str_mv AT kourouklarisandreas postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport
AT ioannoukyriakos postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport
AT athanasiouioannis postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport
AT panagidoualexia postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport
AT demetrioukiproulla postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport
AT zavrosmichalis postpartumthromboticmicroangiopathyrevealedasatypicalhemolyticuremicsyndromesuccessfullytreatedwitheculizumabacasereport